^
    Back
    Association details:
    Biomarker:EGFR mutation + NRAS Q61K
    Cancer:Lung Adenocarcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

    Excerpt:
    ...we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs....Ectopic expression of mutant NRAS or BRAF in drug-sensitive EGFR-mutant cells conferred resistance to EGFR TKIs that was overcome by addition of a MEK inhibitor....The combination of erlotinib and GSK1120212 leads to greater inhibition of cell growth in PC-9 cells stably expressing NRAS Q61K (PC-9/NRAS Q61K cells) (A) or BRAF V600E (PC-9/BRAF V600E cells)...
    DOI:
    https://doi.org/10.1073/pnas.1203530109